Based on safety data presented by the manufacturer, "it is abundantly clear" that all three doses were safer in terms of the risk of hypertensive reactions than the MAO inhibitor
tranylcypromine (Parnate), said Dr.
12 MAO Inhibitors
Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016
Those voting in favor of approval with no restrictions for the 6-mg dose were comfortable that there were no indications of harmful effects in clinical safety data presented by the manufacturer and in the more extensive database on Eldepryl, and cited the benefit of having an MAO inhibitor
with no such restrictions.
achieve superior "triple-action" antidepressant efficacy by elevating the levels of all three of the key neurotransmitters that positively affect mood.
Just as the greater safety of the selective serotonin reuptake inhibitors once enabled millions of patients to benefit from their antidepressant potential, we believe that TriRima could unlock the superior antidepressant potential of the MAO inhibitor
class," said Barry Brand, Chief Executive Officer of CeNeRx.
At oral doses that achieve an antidepressant effect, however, selegiline loses its selectivity, inhibiting both MAO-A and MAO-B and arousing the same safety issues as with other MAO inhibitors
Patients who take nonselective MAO inhibitors
need to be cautious with the foods they eat to prevent an abnormal build-up of tyramine, which could lead to an episode of extremely high blood pressure, potentially leading to stroke or heart attack.
In contrast to other MAO inhibitors
, our third generation RIMA series is designed to bind selectively and reversibly, with the goal of significantly reducing the cardiovascular risks and other side effects typically associated with the MAOI class.
The authors argue that the combination of a MAO inhibitor
with another centrally active serotonergic agent poses significant health risks from MAO inhibitor
poisoning or serotonin syndrome.
antidepressants (for example, isocarboxazid and moclobemide).
Normally, the body can easily control tyramine levels, but a side-effect of MAO inhibitor
antidepressants is that they block the breakdown of the chemical.
Rasagiline, an MAO inhibitor
, improves parkinsonian symptoms, and its potential role in slowing the progression of the degenerative process is being investigated.